Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Alnylam Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2002-01-01

Employees: -

Market Cap: $35.9B

Website: http://www.alnylam.com/

Clinical Trials

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Phase 3

Completed

Conditions: Acute Intermittent Porphyria
Acute Porphyria
Porphyria, Acute Intermittent
Hereditary Coproporphyria (HCP)
Acute Hepatic Porphyria
ALA Dehydratase Deficient Porphyria (ADP)
Variegate Porphyria (VP)

Interventions: Drug: Givosiran
Drug: Placebo

First Posted Date: 2017-11-09

Last Posted Date: 2024-04-22

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 94

Registration Number: NCT03338816

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Phase 2

Withdrawn

Conditions: Atypical Hemolytic Uremic Syndrome

Interventions: Drug: Cemdisiran

First Posted Date: 2017-10-06

Last Posted Date: 2018-10-01

Lead Sponsor: Alnylam Pharmaceuticals

Registration Number: NCT03303313

Locations: 🇸🇪
Clinical Trial Site, Örebro, Sweden

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Phase 1

Completed

Conditions: Acute Intermittent Porphyria

Interventions: Drug: Givosiran

First Posted Date: 2016-10-31

Last Posted Date: 2024-03-12

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT02949830

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Conditions: TTR-mediated Amyloidosis
Amyloidosis, Hereditary
Amyloid Neuropathies, Familial
Familial Amyloid Polyneuropathies
Amyloid Neuropathies
Amyloidosis, Hereditary, Transthyretin-Related

First Posted Date: 2016-10-20

Last Posted Date: 2024-05-20

Lead Sponsor: Alnylam Pharmaceuticals

Registration Number: NCT02939820

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

Phase 1

Terminated

Conditions: Hepatitis B
Chronic Hepatitis B
Hepatitis B, Chronic
Hepatitis B Infection
HBV

Interventions: Drug: ALN-HBV
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2016-07-07

Last Posted Date: 2018-09-24

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT02826018

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Phase 1

Completed

Conditions: Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: ALN-TTRSC02

First Posted Date: 2016-06-14

Last Posted Date: 2018-09-21

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT02797847

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

Phase 1

Completed

Conditions: Primary Hyperoxaluria Type 1 (PH1)

Interventions: Drug: Placebo
Drug: Lumasiran

First Posted Date: 2016-03-11

Last Posted Date: 2020-01-30

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT02706886

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Phase 2

Completed

Conditions: ATTR Amyloidosis
Transthyretin (TTR)-Mediated Amyloidosis
Familial Amyloidotic Polyneuropathy (FAP)
Familial Amyloid Neuropathies

Interventions: Drug: Revusiran

First Posted Date: 2015-11-04

Last Posted Date: 2019-03-28

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT02595983

Locations: 🇬🇧
Clinical Trial SIte, London, United Kingdom
🇸🇪
Clinical Trial Site, Umea, Sweden

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Phase 3

Completed

Conditions: Amyloidosis

Interventions: Drug: Patisiran

First Posted Date: 2015-07-29

Last Posted Date: 2023-12-06

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 211

Registration Number: NCT02510261

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1

Terminated

Conditions: Antitrypsin Deficiency Liver Disease

Interventions: Drug: ALN-AAT
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2015-07-21

Last Posted Date: 2019-01-07

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT02503683

Locations: 🇬🇧
Richmond Pharmacology, Ltd., London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy